Electronic Margin of Safety and NonClinical Toxicology Study Data Submission; Notice of Pilot Project, 65540-65541 [E9-29419]
Download as PDF
65540
Federal Register / Vol. 74, No. 236 / Thursday, December 10, 2009 / Notices
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Skeletal
Biology.
Date: December 16, 2009.
Time: 5:30 p.m. to 7:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
(Telephone Conference Call).
Contact Person: Daniel F. McDonald, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4110,
MSC 7814, Bethesda, MD 20892. (301) 435–
1215. mcdonald@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Urology
Business Applications.
Date: December 21, 2009.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
(Virtual Meeting).
Contact Person: Ryan G. Morris, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4205,
MSC 7814, Bethesda, MD 20892. 301–435–
1501. morrisr@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research; 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: December 4, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–29473 Filed 12–9–09; 8:45 am]
BILLING CODE 4140–01–P
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Muscle and Skeletal Biology.
Date: January 8, 2010.
Time: 9 a.m. to 1 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Yi-Hsin Liu, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4214,
MSC 7814, Bethesda, MD 20892, 301–451–
1327, liuyh@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; RM09–009
and RM009–008: Development of New
Technologies Needed for Studying Human
Microbiome.
Date: January 25, 2010.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Fouad A. El-Zaatari, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3206,
MSC 7808, Bethesda, MD 20814–9692, (301)
435–1149, elzaataf@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: December 4, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–29487 Filed 12–9–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Food and Drug Administration
mstockstill on DSKH9S0YB1PROD with NOTICES
Center for Scientific Review; Notice of
Closed Meetings
[Docket No. FDA–2009–N–0561]
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
Electronic Margin of Safety and
NonClinical Toxicology Study Data
Submission; Notice of Pilot Project
VerDate Nov<24>2008
17:19 Dec 09, 2009
Jkt 220001
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration’s (FDA’s) Center for
Veterinary Medicine (CVM) is seeking
sponsors interested in participating in a
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
pilot project to test the electronic
submission of margin of safety and
nonclinical toxicology study data using
the Standard for Exchange of
Nonclinical Data (SEND), a new
electronic data standard format which is
used to support review activity. FDA
anticipates that a successful pilot will
enable CVM to accept margin of safety
and nonclinical toxicology study data
related to investigational new animal
drug (INAD) files and new animal drug
applications (NADA’s) electronically in
SEND format.
DATES: Submit electronic or written
requests to participate in the pilot
project by March 10, 2010. General
comments on the pilot project are
welcome at any time.
ADDRESSES: Submit electronic requests
to participate in the pilot and comments
regarding the project to https://www.
regulations.gov. Submit written requests
and comments to the Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, rm. 1061, Rockville, MD 20852.
Submit a single copy of electronic
comments or two paper copies of any
mailed comments, except that
individuals may submit one paper copy.
Comments should be identified with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
FOR FURTHER INFORMATION CONTACT:
Janis Messenheimer, Food and Drug
Administration, Center for Veterinary
Medicine, Office of New Animal Drug
Evaluation (HFV–135), 7500 Standish
Pl., Rockville, MD 20855, 240–276–
8348, e-mail: Janis.messenheimer
@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing an opportunity to
participate in a 3-year CVM pilot
project. This pilot involves FDA’s
ongoing testing of SEND, a data model
initially developed for non-clinical data
from animal toxicology studies
submitted in support of applications for
approval of human drugs. This pilot is
designed to test the ability of SEND to
support the review of margin of safety
and nonclinical toxicology study data
submitted to INAD files and as part of
NADA’s at CVM. CVM considers this
pilot to be the beginning of a phased
implementation of SEND that will
enable CVM to receive and evaluate data
from toxicology studies as part of the
human food safety evaluation and
margin of safety studies.
E:\FR\FM\10DEN1.SGM
10DEN1
mstockstill on DSKH9S0YB1PROD with NOTICES
Federal Register / Vol. 74, No. 236 / Thursday, December 10, 2009 / Notices
SEND was developed by the Clinical
Data Interchange Standards
Consortium’s (CDISC’s) SEND Team.
CDISC is an open, multidisciplinary,
nonprofit organization that has
established worldwide industry
standards to support the electronic
acquisition and submission of clinical
trial data and metadata for medical and
biopharmaceutical product
development (https://www.cdisc.org1).
CDISC is currently facilitating and
testing the extension of the same SEND
standard for nonclinical toxicology data.
Where possible, the standards
developed for clinical datasets and
metadata, as described in the overall
Study Data Tabulation Model (SDTM),
are being used to develop a
standardized dataset format for
nonclinical studies.
Recently, the Center for Drug
Evaluation and Research (CDER)
completed a pilot project (phase 1)
using the SEND format in sample
toxicology datasets, that is, outside of a
regulatory setting (68 FR 3885, January
27, 2003). The phase 1 CDER pilot also
evaluated data validation and analysis
tools specifically designed to validate
datasets according to the current SEND
standard and to enable a reviewer to
display and evaluate data efficiently
from animal toxicity studies submitted
in the SEND format. The phase 1 pilot
resulted in the development of a SEND
Implementation Guide (SENDIG)
describing the process for formatting
data from single- and repeat-dose
animal toxicity and carcinogenicity
studies for submission purposes.
Following the phase 1 pilot, CDER
announced a second pilot (phase 2) to
test SEND formatted datasets in a
regulatory setting (72 FR 56363, October
3, 2007). To support the new CDER
pilot, the SENDIG has been updated to
ensure the harmonized implementation
of the CDISC SDTM and SEND models.
The updated guide can be found at
https://www.cdisc.org.
CVM currently receives margin of
safety and nonclinical toxicology study
data in paper, portable document format
(PDF), and other electronic formats. The
lack of uniformity in the formats used
by sponsors to submit data, in addition
to the inconsistent use of terminology
across submissions, complicates the
agency’s efforts to validate, display, and
evaluate the data using modern,
computer-based review and analysis
tools. As part of FDA’s effort to
modernize its information technology
1 FDA has verified the Web site address, but FDA
is not responsible for any subsequent changes to the
Web site address after this document publishes in
the Federal Register.
VerDate Nov<24>2008
17:19 Dec 09, 2009
Jkt 220001
systems and improve efficiency, CVM is
planning to transition to a true
electronic data format for submission of
study data for regulatory review.
II. Pilot Project Description
This pilot is intended to help CVM
evaluate the adequacy of the current
SEND format (SAS transport files, XPT
version 5) in accommodating margin of
safety and nonclinical toxicology study
data submitted to the Center. As part of
this evaluation and in anticipation of
FDA receiving datasets for regulatory
review, the CDISC SEND Team, in
collaboration with FDA and available
pilot participants, will first update the
SENDIG as needed to include
veterinary-specific data elements and
terms.
As experience from the ongoing pilot
is gained with various types of margin
of safety and nonclinical toxicology
study data, CVM expects to recommend
new technical specifications for margin
of safety and toxicology studies as part
of a continuing process of transitioning
from paper-based submissions to the
submission of study data by electronic
means.
III. Participation
CVM is seeking a limited number of
sponsors (approximately five to eight,
but no more than eight) to participate in
this pilot. Because a limited group of
voluntary participants is needed, CVM
will use its discretion in choosing
volunteers, based on their experience
with datasets previously submitted to
CVM. The duration of the pilot is
expected to be approximately 3 years,
but it may be extended as needed. A
familiarity with SEND (e.g., from
involvement in the CDER pilot) would
benefit participants but is not necessary
for participation in the project. A
participant should be willing to provide
the same study data in both paper
format and SEND electronic format
using SAS transport files (XPT version
5). The pilot provides the best
opportunity to compare and evaluate
the same data available in paper and
SEND formats in order to test the
accuracy and reliability of the SEND
format.
For the purposes of this pilot, study
reports from margin of safety and
nonclinical toxicology study data will
be requested for submission. We
anticipate that a successful pilot,
including the implementation of any
needed changes to the SENDIG and/or
the data validation, viewing, and
analysis tools, will allow CVM to accept
specific types of margin of safety and
nonclinical toxicology study data
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
65541
electronically based on the SEND
format.
Requests to participate in the pilot
project should be submitted to the
Division of Dockets Management (see
ADDRESSES). Requests are to be
identified with the docket number
found in brackets in the heading of this
document.
Under current FDA regulations,
applicants must provide evidence to
establish safety and effectiveness as part
of their NADA (21 CFR 514.1(b)(8)).
Participation in this pilot program will
not exempt participants from
compliance with applicable
requirements for the submission of
evidence to establish safety and
effectiveness.
IV. Comments
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES) electronic or written
comments regarding this pilot project.
Submit a single copy of electronic
comments or two paper copies of any
mailed comments, except that
individuals may submit one paper copy.
Comments are to be identified with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
Dated: December 4, 2009.
David Horowitz,
Assistant Commissioner for Policy.
[FR Doc. E9–29419 Filed 12–9–09; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HOMELAND
SECURITY
Federal Emergency Management
Agency
[Docket ID: FEMA–2009–0001]
Agency Information Collection
Activities: Proposed Collection;
Comment Request, 1660–0105;
Community Preparedness and
Participation Survey
AGENCY: Federal Emergency
Management Agency, DHS.
ACTION: Notice; 60-day notice and
request for comments; revision of a
currently approved information
collection; OMB No. 1660–0105; 088–0–
2, Household Preparedness Telephone
Survey.
SUMMARY: The Federal Emergency
Management Agency, as part of its
continuing effort to reduce paperwork
and respondent burden, invites the
E:\FR\FM\10DEN1.SGM
10DEN1
Agencies
[Federal Register Volume 74, Number 236 (Thursday, December 10, 2009)]
[Notices]
[Pages 65540-65541]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-29419]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2009-N-0561]
Electronic Margin of Safety and NonClinical Toxicology Study Data
Submission; Notice of Pilot Project
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration's (FDA's) Center for
Veterinary Medicine (CVM) is seeking sponsors interested in
participating in a pilot project to test the electronic submission of
margin of safety and nonclinical toxicology study data using the
Standard for Exchange of Nonclinical Data (SEND), a new electronic data
standard format which is used to support review activity. FDA
anticipates that a successful pilot will enable CVM to accept margin of
safety and nonclinical toxicology study data related to investigational
new animal drug (INAD) files and new animal drug applications (NADA's)
electronically in SEND format.
DATES: Submit electronic or written requests to participate in the
pilot project by March 10, 2010. General comments on the pilot project
are welcome at any time.
ADDRESSES: Submit electronic requests to participate in the pilot and
comments regarding the project to https://www.regulations.gov. Submit
written requests and comments to the Division of Dockets Management
(HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852. Submit a single copy of electronic comments or two
paper copies of any mailed comments, except that individuals may submit
one paper copy. Comments should be identified with the docket number
found in brackets in the heading of this document. Received comments
may be seen in the Division of Dockets Management between 9 a.m. and 4
p.m., Monday through Friday.
FOR FURTHER INFORMATION CONTACT: Janis Messenheimer, Food and Drug
Administration, Center for Veterinary Medicine, Office of New Animal
Drug Evaluation (HFV-135), 7500 Standish Pl., Rockville, MD 20855, 240-
276-8348, e-mail: Janis.messenheimer@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing an opportunity to participate in a 3-year CVM
pilot project. This pilot involves FDA's ongoing testing of SEND, a
data model initially developed for non-clinical data from animal
toxicology studies submitted in support of applications for approval of
human drugs. This pilot is designed to test the ability of SEND to
support the review of margin of safety and nonclinical toxicology study
data submitted to INAD files and as part of NADA's at CVM. CVM
considers this pilot to be the beginning of a phased implementation of
SEND that will enable CVM to receive and evaluate data from toxicology
studies as part of the human food safety evaluation and margin of
safety studies.
[[Page 65541]]
SEND was developed by the Clinical Data Interchange Standards
Consortium's (CDISC's) SEND Team. CDISC is an open, multidisciplinary,
nonprofit organization that has established worldwide industry
standards to support the electronic acquisition and submission of
clinical trial data and metadata for medical and biopharmaceutical
product development (https://www.cdisc.org\1\). CDISC is currently
facilitating and testing the extension of the same SEND standard for
nonclinical toxicology data. Where possible, the standards developed
for clinical datasets and metadata, as described in the overall Study
Data Tabulation Model (SDTM), are being used to develop a standardized
dataset format for nonclinical studies.
---------------------------------------------------------------------------
\1\ FDA has verified the Web site address, but FDA is not
responsible for any subsequent changes to the Web site address after
this document publishes in the Federal Register.
---------------------------------------------------------------------------
Recently, the Center for Drug Evaluation and Research (CDER)
completed a pilot project (phase 1) using the SEND format in sample
toxicology datasets, that is, outside of a regulatory setting (68 FR
3885, January 27, 2003). The phase 1 CDER pilot also evaluated data
validation and analysis tools specifically designed to validate
datasets according to the current SEND standard and to enable a
reviewer to display and evaluate data efficiently from animal toxicity
studies submitted in the SEND format. The phase 1 pilot resulted in the
development of a SEND Implementation Guide (SENDIG) describing the
process for formatting data from single- and repeat-dose animal
toxicity and carcinogenicity studies for submission purposes. Following
the phase 1 pilot, CDER announced a second pilot (phase 2) to test SEND
formatted datasets in a regulatory setting (72 FR 56363, October 3,
2007). To support the new CDER pilot, the SENDIG has been updated to
ensure the harmonized implementation of the CDISC SDTM and SEND models.
The updated guide can be found at https://www.cdisc.org.
CVM currently receives margin of safety and nonclinical toxicology
study data in paper, portable document format (PDF), and other
electronic formats. The lack of uniformity in the formats used by
sponsors to submit data, in addition to the inconsistent use of
terminology across submissions, complicates the agency's efforts to
validate, display, and evaluate the data using modern, computer-based
review and analysis tools. As part of FDA's effort to modernize its
information technology systems and improve efficiency, CVM is planning
to transition to a true electronic data format for submission of study
data for regulatory review.
II. Pilot Project Description
This pilot is intended to help CVM evaluate the adequacy of the
current SEND format (SAS transport files, XPT version 5) in
accommodating margin of safety and nonclinical toxicology study data
submitted to the Center. As part of this evaluation and in anticipation
of FDA receiving datasets for regulatory review, the CDISC SEND Team,
in collaboration with FDA and available pilot participants, will first
update the SENDIG as needed to include veterinary-specific data
elements and terms.
As experience from the ongoing pilot is gained with various types
of margin of safety and nonclinical toxicology study data, CVM expects
to recommend new technical specifications for margin of safety and
toxicology studies as part of a continuing process of transitioning
from paper-based submissions to the submission of study data by
electronic means.
III. Participation
CVM is seeking a limited number of sponsors (approximately five to
eight, but no more than eight) to participate in this pilot. Because a
limited group of voluntary participants is needed, CVM will use its
discretion in choosing volunteers, based on their experience with
datasets previously submitted to CVM. The duration of the pilot is
expected to be approximately 3 years, but it may be extended as needed.
A familiarity with SEND (e.g., from involvement in the CDER pilot)
would benefit participants but is not necessary for participation in
the project. A participant should be willing to provide the same study
data in both paper format and SEND electronic format using SAS
transport files (XPT version 5). The pilot provides the best
opportunity to compare and evaluate the same data available in paper
and SEND formats in order to test the accuracy and reliability of the
SEND format.
For the purposes of this pilot, study reports from margin of safety
and nonclinical toxicology study data will be requested for submission.
We anticipate that a successful pilot, including the implementation of
any needed changes to the SENDIG and/or the data validation, viewing,
and analysis tools, will allow CVM to accept specific types of margin
of safety and nonclinical toxicology study data electronically based on
the SEND format.
Requests to participate in the pilot project should be submitted to
the Division of Dockets Management (see ADDRESSES). Requests are to be
identified with the docket number found in brackets in the heading of
this document.
Under current FDA regulations, applicants must provide evidence to
establish safety and effectiveness as part of their NADA (21 CFR
514.1(b)(8)). Participation in this pilot program will not exempt
participants from compliance with applicable requirements for the
submission of evidence to establish safety and effectiveness.
IV. Comments
Interested persons may submit to the Division of Dockets Management
(see ADDRESSES) electronic or written comments regarding this pilot
project. Submit a single copy of electronic comments or two paper
copies of any mailed comments, except that individuals may submit one
paper copy. Comments are to be identified with the docket number found
in brackets in the heading of this document. Received comments may be
seen in the Division of Dockets Management between 9 a.m. and 4 p.m.,
Monday through Friday.
Dated: December 4, 2009.
David Horowitz,
Assistant Commissioner for Policy.
[FR Doc. E9-29419 Filed 12-9-09; 8:45 am]
BILLING CODE 4160-01-S